MET and pancreatic adenocarcinoma: Previous reports regarding the expression of integrin αvβ6 (85–100 %), cMET (82–100 %), EGFR (36–69 %), EpCAM (56–78 %), HER2 (16–69 %), and VEGFR2 (64–93 %) in pancreatic adenocarcinoma are consistent with our results [31–47].